Chagas drug licensed to nonprofit

The nation’s first nonprofit pharmaceutical company has licensed a new class of compounds from Yale and the University of Washington that could lead to treatments for the parasitic Chagas disease, which affects between 16 and 18 million people, mostly in Latin America.

The compounds, called azoles, were developed by teams led by Andrew D. Hamilton, Ph.D., deputy provost for science and technology at Yale, in collaboration with faculty at the University of Washington. Azoles inhibit production of a chemical that is necessary for the survival of the parasite Trypanosomacruzi without harming human cells.

The Institute for OneWorld Health in San Francisco will have exclusive license to develop azole compounds.

Other Roundup

Late neuroscientist honored

In recognition of her pioneering work on the brain’s frontal lobe and her studies of the cerebral...


Download on the Apple App Store